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Body temperature abnormalities, which occur because of several infectious and non-infectious etiologies, are
among the most commonly noted symptoms of critically ill patients. These abnormalities frequently trigger changes
in patient management. The purpose of this article was to review the contemporary literature investigating the
definition and occurrence of body temperature abnormalities in addition to their impact on illness severity and
mortality in critically ill non-neurological patients, particularly in patients with severe sepsis. Reports on the influence
of fever on outcomes are inconclusive, and the presence of fever per se may not contribute to increased mortality
in critically ill patients. In patients with severe sepsis, the impacts of elevated body temperature and hypothermia
on mortality and the severity of physiologic decline are different. Hypothermia is significantly associated with an
increased risk of mortality. In contrast, elevated body temperature may not be associated with increased disease
severity or risk of mortality. In patients with severe sepsis, the effect of fever and fever control on outcomes requires
further research.
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Body temperature is a routinely measured vital sign in
all patients admitted to the intensive care unit (ICU).
Body temperature abnormalities are among the most
commonly noted symptoms of critically ill patients, and
they occur because of several different infectious and
non-infectious etiologies. Moreover, these abnormalities
frequently trigger changes in patient management [1,2].
Fever occurs in approximately half of the patients ad-
mitted to the ICU and is reported to be associated with
adverse outcomes [3], although its incidence in adult pa-
tients in the ICU may decrease in recent years [4]. Fever
is part of a host’s acute phase response to infectious as
well as non-infectious inflammatory stimuli [5] and, as
such, is one of the most prominent symptoms of infec-
tion [2]. Fever is believed to be harmful, especially in pa-
tients with life-threatening illnesses, because febrile* Correspondence: kussie@emergency-medicine.med.tohoku.ac.jp
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article, unless otherwise stated.responses are known to increase the metabolic rate, mi-
nute ventilation, and oxygen consumption; therefore, it
can have adverse effects on neurological outcomes [6-8].
Conversely, the beneficial effects of fever may include re-
duction in bacterial growth and promotion of antibody
and cytokine synthesis, thereby activating immune cells
and improving survival [9-11]. Several studies have also
suggested that suppression of the febrile response with
antipyretic drugs could worsen patient outcomes [12,13].
Hypothermia can be caused by a number of factors, in-
cluding cold exposure, severe infection, endocrine abnor-
malities, and drug overdose, all of which require intensive
care [14-16]. Inflammation-associated hypothermia is con-
sidered a thermoregulatory ‘failure’ [17], and it has been
recognized as a significant clinical condition. Although
hypothermia may be an unintended consequence of crit-
ical illness in patients with infectious and non-infectious
conditions, the influence of hypothermia on the physio-
logical severity and outcome of critically ill patients is not
well understood [18-25].
The purpose of this article was to review the contem-
porary literature investigating the definition and occur-
rence of body temperature abnormalities in addition totral Ltd. This is an Open Access article distributed under the terms of the
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ically ill non-neurological patients, especially in patients
with severe sepsis.
A literature review was conducted using PubMed
(Bethesda, MD, USA) from 1966 to November 30, 2013,
to identify articles focusing on the epidemiology of
temperature abnormalities, their impact on severity and
mortality, and their management in the ICU. Search terms
included fever, hyperthermia, hypothermia, temperature,
and ICU. Abstracts were screened for relevance, and ap-
propriate full-length articles were retrieved for appraisal.
The reference lists of significant articles were also screened
for other pertinent articles.
Review
Normal body temperature and fever definition
Although it varies over the course of the day, normal
body temperature is approximately 37.0°C (98.6°F) and is
controlled in the thermoregulatory center of the anterior
hypothalamus [26]. A normal variation of 0.5°C (0.9°F)
occurs within individuals depending on the time of day
[27]. Based on a study conducted in 148 healthy adults,
a morning temperature of >37.2°C or an afternoon
temperature of >37.7°C was considered as a fever [28].
Oral temperatures from more than 700 measurements
in these adults ranged from 35.6°C to 38.5°C with a
mean of 36.8°C ± 0.4°C [28]. Lower levels occurred at
6 A.M., and higher levels occurred between 4 and 6 P.M.
The 99th percentile for healthy adults was indicated by
the maximum normal oral temperature of 37.2°C at
6 A.M. and 37.7°C at 4 P.M., thus providing the basis for
fever cutoffs, which differed based on time of day.
Because of this variability and given that the magnitude
and significance of an elevated temperature will depend
on the specific patient population, a wide range of defini-
tions for fever have been reported in the literature, and
there is currently no consensus. Although a core body
temperature of 38.0°C is used as the cutoff value for fever
in several definitions [26,29,30], a core temperature of
38.3°C (101°F) may be more generally accepted to repre-
sent fever in ICU patients, and this temperature is recom-
mended in the guidelines for the evaluation of a new fever
in critically ill adult patients [2].
An exact temperature measurement is critical to patient
management. Oral thermometers are impractical, and ax-
illary temperature measurements are not recommended in
critically ill patients, which significantly underestimate
true temperature [2]. Therefore, in the ICU, temperature
is measured using a number of different methods, includ-
ing thermistors on intravascular, bladder, esophageal, or
rectal probes, in addition to infrared tympanic membrane
and temporal artery thermometers. Although the pulmon-
ary artery catheter has been considered the ‘gold standard’
measurement technique, in most situations, relativelysmall differences exist between the other commonly used
methods [2,31].
Fever and hyperthermia
The major causes of abnormally elevated temperatures in
critically ill patients can be broadly classified as infectious
fevers, non-infectious fevers, and hyperthermia syn-
dromes [1,32]. Infectious etiologies of fever include bac-
terial, viral, fungal, parasitic, and protozoal types.
Bacterial infections are the most common etiology and
are typically associated with positive cultures. The most
common sites of bacterial infection in critically ill pa-
tients are the lower respiratory tract, urinary tract, pri-
mary bloodstream, and intra-abdominal region [33-36].
Non-infectious causes of fever are also common and in-
clude myocardial infarction, pancreatitis, drug hyper-
sensitivity reactions, transfusion reactions, venous
thromboembolic disease, deep body site hematomas, and
neurogenic fever such as that following subarachnoid
hemorrhage. Hyperthermia syndromes include heat
stroke, neuroleptic malignant syndrome, malignant
hyperthermia, severe thyrotoxicosis, pheochromocytoma,
and adrenal crisis [1,37,38].
The thermostat device, which regulates the room
temperature in a home, is comparable to the way the
hypothalamus controls core body temperature. The
thermostat setting in the hypothalamic thermoregulatory
center shifts upwards during a fever due to infectious or
non-infectious causes, i.e., during fever, the ‘set point’ in
the hypothalamus shifts upwards from the ‘normother-
mia’ setting to febrile levels. Elevated levels of prosta-
glandin E2 in the hypothalamus appear to trigger the
increased set point, resulting in the activation of neurons
in the vasomotor center that commence vasoconstric-
tion and of warm-sensing neurons that slow their firing
rate and increase heat production in the periphery [39].
In contrast to the actions during fever, the setting of
the thermoregulatory center during hyperthermia re-
mains unchanged at normothermic levels, while body
temperature increases in an uncontrolled fashion and
overrides the ability to lose heat. Exogenous heat expos-
ure and endogenous heat production are two mecha-
nisms by which hyperthermia can result in dangerously
high internal temperatures [39].
Because there are no clear medical definitions for fever
or hyperthermia in critically ill patients, the definitions
used within each study in this review differed. Abnor-
mally elevated temperatures were categorized as fever,
which is controlled by the hypothalamic thermoregula-
tory center, or hyperthermia, in which the body
temperature increases without control by the thermo-
regulatory center. In addition, high fever was defined
as fever with markedly elevated body temperatures
(e.g., >39.5°C) in several studies. Therefore, in this review,
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based on the definition(s) in each study.
Body temperature abnormalities and mortality in ICU
patients
Reports of the impact of fever on mortality in ICU pa-
tients are inconsistent; some studies indicate that fever
may contribute to mortality, while a recent meta-analysis
has suggested that the presence of fever per se may not in-
crease mortality [40]. Peres Bota et al. reported that pa-
tients with fever had significantly increased mortality
compared to patients with normothermia (35.3% vs.
10.3%, P < 0.01) in a prospective study of fever among 493
adult ICU patients [21]. Fever (core temperature ≥38.3°C)
in 139 (28.2%) patients was primarily present at ICU ad-
mission (76.3%) and was of infectious origin (55%). The
most common non-infectious cause of fever was postoper-
ative fever (19%). Circiumaru et al. prospectively studied
fever (core temperature ≥38.4°C) in 100 consecutive ad-
missions of 93 patients over a 4-month period and found
fever among 70% of admissions [41]. There were similar
proportions of infectious and non-infectious etiologies,
and most fevers lasted <5 days. The presence of prolonged
fever (>5 days) was associated with increased mortality
(62.5% vs. 29.6% for prolonged fever and fever, respect-
ively, P < 0.0001).
Laupland et al. studied fever in 20,466 critically ill
adult patients with and without infection from 2000 to
2006 [3]. The cumulative incidences of fever (core
temperature ≥38.3°C) and high fever (core temperature
≥39.5°C) were 44% and 8%, respectively. Positive bacter-
ial cultures were associated with 17% and 31% of the
fever and high fever episodes, respectively. Although the
presence of fever was not associated with increased mor-
tality, the presence of high fever was associated with a
significantly increased risk of death (12% vs. 20.3%, re-
spectively, P < 0.0001). It was suggested that high fever
could result in complications such as cardiac arrhyth-
mias, tachycardia, increased oxygen demand, convul-
sions, and brain damage [3].
Regarding the association of fever with mortality in
ICU patients, the impact of fever is inconsistent, and the
presence of fever itself may not contribute to the in-
crease in mortality as suggested in a recent meta-
analysis [40]. However, more specifically, high fevers
(≥39.5°C) and prolonged fevers (>5 days) may be associ-
ated with an increased risk of mortality [40,42].
Comparatively, limited attention has been given to
hypothermia, which has also been associated with an in-
creased risk of mortality in critically ill patients
[18,20,21,43]. Laupland et al. evaluated 10,962 ICU pa-
tients, and 10% of the patients had mild hypothermia
(35.0°C–35.9°C), 5% had moderate hypothermia (32°C–
34.9°C), 1% had severe hypothermia (<32°C), 21%patients had a mild fever (38.3°C–39.4°C), and 5% had a
high fever (>39.5°C) at presentation. Normothermia was
present in 6,133 patients (55%). The overall mortality in
these ICU patients was 18%: 14% with normothermia,
22% with mild hypothermia, 38% with moderate
hypothermia, 60% with severe hypothermia, 18% with
mild fever, 21% with high fever, and 30% with mixed
temperature abnormalities. Although fever at presenta-
tion was not associated with a significantly increased risk
of death, hypothermia was an independent predictor for
death in medical ICU patients [43]. Therefore,
hypothermia may be a major and potentially modifiable
factor associated with an increased risk of death in critic-
ally ill patients.
Body temperature abnormalities in patients with severe
sepsis
Fever may not be always associated with an increased
risk of mortality in patients with sepsis. A recent retro-
spective study with data from Australia, New Zealand,
and the UK reported that an elevated peak body
temperature in the first 24 h after ICU admission was
associated with decreased in-hospital mortality in pa-
tients with infection [18]. The lowest mortality risk was
among patients with a temperature between 39°C and
39.4°C. However, mortality risk was increased among pa-
tients with the same temperature range who did not
have infection.
Similarly, the Fever and Antipyretic in Critically Ill Pa-
tients Evaluation (FACE) study observed a trend for de-
creased 28-day mortality in septic patients with
temperatures ≥39.5°C, whereas the opposite was demon-
strated for non-septic patients with temperatures ≥39.5°C
[44]. Swenson et al. prospectively analyzed 823 adult surgi-
cal ICU patients with sepsis related to bloodstream infec-
tions between 1996 and 2005 in which fever was defined
as a temperature ≥38.5°C [45]. Death occurred in 148 pa-
tients with bloodstream infections (18.0%), and 541
(65.7%) patients were febrile at diagnosis. The mortality in
the patients with and without fever was 12.9% and 27.7%,
respectively (P < 0.0001). A higher maximum temperature
was protective against mortality (OR = 0.60, P < 0.0001).
As a result, the authors suggested that fever during a
bloodstream infection improves survival in surgical pa-
tients with sepsis.
In contrast, hypothermia may be associated with an in-
creased risk of mortality in patients with severe sepsis
[18,20,21,43] as evidenced by previous large trials
(Table 1) [16,19,46-48]. The incidence of hypothermia
(<35.5°C) was 9% in the Methylprednisolone Severe Sep-
sis Study, 10% in the Veterans Administration Systemic
Sepsis Cooperative Study of Glucocorticoid Therapy,
and 9.6% in the Ibuprofen Sepsis Study, and all of these
studies only included patients with severe sepsis. The
Table 1 Incidence of hypothermia (body temperature






Sepsis Study [16] (n = 382), 9%
62 26
Veterans Administration Systemic Sepsis
Cooperative Study of Glucocorticoid
Therapy [47] (n = 223), 10%
57 28
Ibuprofen Sepsis Study [19]
(n = 453), 9.6%
70 35
NORASEPT II Study (tissue factor pathway inhibitor)
[46], (n = 930, septic shock), 21%
59 34
JAAM Sepsis Registry [49] (n = 624), 15.9% 40.4 17.7
JAAM Japanese Association for Acute Medicine.
Table 2 Body temperature of ICU admission and 28-day











≤35.5 40.4 3.096 1.611–5.947 0.001
35.6–36.5 34.4 2.032 1.009–4.088 0.047
36.6–37.5 20.5 1 Reference
37.6–38.5 18.1 0.853 0.461–1.577 0.621
38.6–39.5 15.8 0.726 0.377–1.395 0.404
≥39.6 17.2 0.803 0.363–1.778 0.693
Table 3 Characteristics and outcomes in patients with






Septic shock 59.4% (n = 95) 40.3% (n = 187) <0.001
SOFA score 10 (7–13) 8 (5–11) <0.001
APACHE II score 26 (21–32) 21 (16.25–27) <0.001
Outcome
28-day mortality 38.1% (n = 61) 17.9% (n = 83) <0.001
Hospital mortality 49.4% (n = 79) 22.6% (n = 105) <0.001
Hypothermia is defined as body temperature ≤36.5°C. SOFA Sequential Organ
Failure Assessment, APACHE Acute Physiology and Chronic Health Evaluation
(adapted from [49]).
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hypothermia compared to those without hypothermia in
these studies was 62% vs. 26%, 57% vs. 28%, and 70% vs.
35%, respectively. The incidence of hypothermia in the
NORASEPT II Study, in which only patients with septic
shock were included, was 21%. The mortality in patients
with hypothermia and in those without hypothermia was
59% and 34%, respectively. The findings of the recent
study that we conducted are also consistent with these
results (Table 1) [49]. In summary, hypothermia may
complicate severe sepsis in approximately 10% to 20% of
patients and could be associated with a risk of mortality
that is twice that of non-hypothermic patients.
Although there are several reports of body temperature
abnormalities in patients with sepsis, there is a relative
paucity of information on the influences of hyperthermia
or hypothermia on disease severity and outcomes in pa-
tients with severe sepsis. We investigated the association
between body temperature, disease severity, and patient
outcomes in patients with a definitive diagnosis of severe
sepsis in a prospective, multicenter, observational study
[49]. Six hundred and twenty-four patients with severe
sepsis were grouped according to their core body
temperature into six categories based on the temperature
data of the Acute Physiology and Chronic Health Evalu-
ation II (APACHE II): ≤35.5°C, 35.6°C–36.5°C, 36.6°C–
37.5°C, 37.6°C–38.5°C, 38.6°C–39.5°C, and ≥39.6°C.
Patients with temperature of ≤36.5°C had significantly
worse Sequential Organ Failure Assessment (SOFA)
scores when compared with patients with temperature
>37.5°C on the day of enrollment. Although mortality did
not relate to body temperature ranges of ≥37.6°C as com-
pared to the reference range of 36.6°C–37.5°C, the relative
risk for 28-day mortality was significantly greater in pa-
tients with 35.6°C–36.5°C and ≤35.5°C (odds ratio 2.032
and 3.096, respectively) (Table 2). When the patients were
divided into groups based on the presence (≤36.5°C, n =160) or absence (>36.5°C, n = 464) of hypothermia, those
with hypothermia had worse physiological severity and
significantly higher 28-day and hospital mortality rates
than those without hypothermia (Table 3). The presence
of hypothermia was an independent predictor of 28-day
mortality, and the differences between the patients with
and without hypothermia were observed irrespective of
the presence of septic shock.
Treatment of fever in critically ill patients and patients
with severe sepsis
Several studies have suggested that the suppression of
the febrile response with antipyretic drugs could worsen
patient outcomes; however, this conclusion is based on
clinical trials that were of insufficient sample sizes to de-
tect differences in mortality [12,13,50-52]. A meta-
analysis by Hammond and Boyle demonstrated that in
critically ill patients, including those with neurological
injury, newer methods of physical cooling and continu-
ous infusions of antipyretic pharmacotherapy more ef-
fectively lowered temperature than conventional physical
cooling and bolus dosing of pharmacologic antipyretic
therapy, respectively [53]. Another meta-analysis demon-
strated that antipyretic therapy does not significantly im-
pact mortality in septic patients (pooled OR 1.08, 95%
CI 0.6–1.96) [54]. Although antipyretic therapy in critic-
ally ill adult patients may be safe and feasible [55], the
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critically ill patients is still unknown.
Conflicting results have been reported by recent stud-
ies investigating mortality in relation to fever control in
patients with sepsis by using antipyretic treatment or ex-
ternal cooling [44,56]. In the FACE study, the independ-
ent association of fever and the use of antipyretic
treatments on mortality in critically ill non-neurological
patients with and without sepsis (n = 1,425) was investi-
gated. They reported that treatment with non-steroidal
anti-inflammatory drugs (NSAIDs) or acetaminophen in-
dependently increased 28-day mortality in septic patients
(NSAIDs: adjusted OR 2.61, P = 0.028; acetaminophen:
adjusted OR 2.05, P = 0.01), but not in non-septic pa-
tients [44]. Fever control by external cooling for vaso-
pressor requirements in septic shock has been evaluated
in a multicenter, randomized, controlled trial [56]. Fe-
brile patients with septic shock requiring vasopressors,
mechanical ventilation, and sedation were allocated
to external cooling (n = 101) to achieve normothermia
(36.5°C–37°C) for 48 h or no external cooling (n = 99).
The primary endpoint was the number of patients with a
50% decrease in the baseline vasopressor dose after 48 h.
A decrease in the vasopressor dose was significantly
more common with external cooling after 12 h of treat-
ment (54% vs. 20%; absolute difference, 34%; 95% CI −46
to −21, P < 0.001). Shock reversal during the ICU stay
was significantly more common with cooling, and the
cooling group had significantly lower 14-day mortality
(19% vs. 34%; absolute difference, −16%; 95% CI −28
to −4, P = 0.013). Therefore, fever control using external
cooling may decrease vasopressor requirements and
early mortality during septic shock. However, further re-
search is required to elucidate the role of fever and its
control in patients with severe sepsis [57].
Conclusions
Body temperature abnormalities are among the most
commonly noted symptoms in critically ill patients. Re-
ports of the influence of fever on the outcomes in these
patients are inconsistent, and the presence of fever per
se may not contribute to increased mortality in critically
ill patients. In patients with severe sepsis, the impacts of
elevated body temperature and hypothermia on mortal-
ity and the severity of physiologic decline are different.
Elevated body temperature alone may not influence dis-
ease severity or mortality; however, hypothermia has
been associated with a significant increase in mortality
risk. Further research regarding the role of body
temperature abnormalities in the risk of mortality is
warranted.
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